Valeo Pharma Inc., a Canadian pharmaceutical company, notes from the news release issued by Novartis on June 30, 2023 that Novartis has agreed to sell XIIDRA®, a prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease, as well as several other ophthalmology products to Bausch + Lomb Corporation. SIMBRINZA® is not part of the products that are being divested by Novartis. The sale is expected to close before the end of the year.
Valeo entered into a 7-year Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. in July 2022 for the Canadian rights to XIIDRA® and SIMBRINZA® and its Ophthalmology business unit is engaged in commercial and medical activities for both products.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!